Tagged with MP

China Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for the future of access and innovation in the world’s second largest market.   With the tremendous development of China’s innovative…

France How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player which turns over around EUR 600 million annually – seems to have hit upon a solution: continuous adaptation.   “What…

MEA For medtech companies operating in the Middle East and Africa, bringing high-tech devices to market alone is no longer enough; reliability, uptime, and lifecycle performance have become just as critical.   Leading players such as Olympus Medical Systems are differentiating themselves by investing in service capability, ensuring that engineers responsible…

USA Loretta Beine, Senior Director of Industry Development for Life Sciences, Empire State Development (ESD) explains the organization’s broader role in growing New York State’s life sciences sector beyond direct funding. As New York State’s chief economic development agency, ESD focuses on supporting startups, attracting new investment, and job creation to…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

Switzerland The first company to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, Madrigal Pharmaceuticals is redefining how the world tackles fatty liver disease. From its new European base in Zug, the firm is building an entirely new therapeutic category while spearheading one of the most ambitious global launches…

China In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis worth up to USD 6 billion. These Novartis deals could come to be one of the largest ever tie-ups between…

Global Pharma executives are used to navigating complexity, but few periods have tested their judgement like the present. As Brendan Shaw writes, between Washington’s renewed push for “most favoured nation” (MFN) drug pricing, fresh waves of US tariffs, and a volatile global policy mood, the rules of engagement for global pharma…

China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…

Puerto Rico In cell and gene therapy, where R&D and manufacturing are inseparable, Puerto Rico’s strong biopharma base makes it an attractive option for CGT companies.   The first mover in this space is CytoImmune. Founded in 2017 by a cadre of Big Pharma veterans and established in Puerto Rico in 2020,…

China With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set to more than double by 2031. While global players like Santen have taken an early lead, a new wave of…

Switzerland Switzerland has long been recognised as a centre of scientific excellence, and in the field of Advanced Therapy Medicinal Products (ATMPs), it is quickly becoming a regulatory trailblazer. In this in-depth conversation, Julia Djonova, Head of ATMPs at Swissmedic, shares how the agency is positioning itself at the forefront of…